Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 2/20 | 0.38 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 6/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | USP10 | Q14694 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | USP13 | Q92995 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129162 | 0.91 | PDE5A (0.43) | MEN1KMT2ALMNAMAPTUSP1 | |
| SCHEMBL5129091 | 0.89 | USP1 (0.44) | USP1WDR48 | |
| SCHEMBL5128845 | 0.87 | FLT3 (0.41) | MEN1KMT2ALMNAMAPTUSP1 | |
| SCHEMBL5127701 | 0.86 | PRKCI (0.47) | MEN1KMT2ALMNAMAPTUSP1 | |
| SCHEMBL5130392 | 0.85 | USP1 (0.43) | MEN1KMT2ALMNAMAPTUSP1 | |
| SCHEMBL5115451 | 0.85 | MEN1 (0.46) | MEN1KMT2ALMNAMAPTAPP | |
| SCHEMBL5130003 | 0.85 | USP1 (0.47) | MEN1KMT2ALMNAMAPTUSP1 | |
| SCHEMBL5123478 | 0.85 | USP1 (0.41) | MEN1KMT2ALMNAMAPTUSP1 | |
| SCHEMBL5121947 | 0.84 | PDE5A (0.43) | MEN1KMT2APDE5A | |
| SCHEMBL5128125 | 0.83 | HTT (0.39) | MEN1KMT2ALMNAMAPTUSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | MEN1 696/4885KMT2A 388/4885LMNA 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.